Direct and Indirect Costs of Influenza-Like Illness Treated with and Without Oseltamivir in 15 European Countries: A Descriptive Analysis Alongside the Randomised Controlled ALIC4E Trial.
Xiao LiJoke BilckeAlike W van der VeldenEmily BongardRobin BruyndonckxPär-Daniel SundvallNicolay Jonassen HarbinSamuel CoenenNick A FrancisPascale BrunoAna García-SangenísDominik GlinzKatarzyna KosiekRéka Mikó-PauerRuta Radzeviciene JurguteBohumil SeifertNikolaos TsakountakisRune Munck AabenhusChristopher C ButlerPhilippe BeutelsPublished in: Clinical drug investigation (2021)
The average direct and indirect costs were consistently lower in patients treated with oseltamivir than in patients without from four perspectives (excluding the oseltamivir cost). However, these differences were not statistically significant.